Background {#Sec1}
==========

Oxyphilic cells, also known as Hurthle cells, are present in some thyroid tumors and nontumor tissues, such as thyroiditis and nodular goiter \[[@CR1]\]. Thyroid oxyphilic tumors, also known as Hurthle cell tumors, refer to those thyroid tumors that entirely or predominantly (\> 75%) consist of oxyphilic thyroid follicular cells \[[@CR2]\]. Thyroid oxyphilic tumors have been identified by the World Health Organization as a special type of tumor of the thyroid follicles that are distinguished from thyroid follicular tumors \[[@CR3]\]. Thyroid oxyphilic tumors can be benign (Hurthle cell adenoma) or malignant (Hurthle cell carcinoma, HCC). HCC is characterized by capsule invasion and/or vascular invasion. Hurthle cell adenocarcinoma is a rare invasive thyroid malignancy, accounting for 3 to 4% of all thyroid malignancies.

Compared to differentiated thyroid carcinoma, HCC has high risk of lymph node metastasis and distant metastasis and is less sensitive to radioiodine therapy \[[@CR4], [@CR5]\]. HCC is a rare disease with unique pathological characteristics and biological behaviors. There is still no consensus on its best surgical treatment method. Our study aimed to find out the characteristics and survival factors of HCC by analyzing patient data from the Surveillance, Epidemiology, and End Results (SEER) database.

Methods {#Sec2}
=======

Data collection {#Sec3}
---------------

All patients diagnosed with oxyphilic adenocarcinoma between 2004 and 2015 according to the International Classification of Disease were identified in the SEER database. Data of patient demographics, surgeries, postoperative treatments, tumor pathology, SEER stage, and disease-specific survival were collected. The SEER stage was used for tumor staging \[[@CR6]\].

Statistical analysis {#Sec4}
--------------------

Demographic, tumor features, and treatment methods were summarized with descriptive statistics. Continuous data are presented as means and standard deviations. Categorical data are presented as counts or percentages. Comparisons of the continuous data were made using the one-way ANOVA test followed by the Tukey's post-hoc test for between three groups or using the independent student t-test for between two groups. Univariate and multivariate Cox proportional hazard models were used to assess the relative impacts of risk factors for HCC. Kaplan-Meier survival curves were constructed for cancer-specific mortality, while the differences between the curves were tested by the log-rank test. All statistical analyses were conducted with SPSS 25.0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism 7 (GraphPad Software, CA, USA). *P* \< 0.05 was considered statistically significant.

Results {#Sec5}
=======

Patient characteristics {#Sec6}
-----------------------

A total of 3084 HCC patients were identified in the database, accounting for 2.4% of all differentiated thyroid carcinoma and 6.67% of follicular thyroid carcinoma patients in the same period. Among them, 2101 patients had comprehensive detailed information and were included in the analysis. Patients were divided into three groups according to the SEER stage (local, regional, and distant). The patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. Table 1Patient characteristicsPatient number, n2101Age, year55.42 ± 15.27Gender, n (%) Male606 (28.84) Female1495 (71.16)Age, year  \< 45508 (24.18)  ≥ 451593 (75.82)Race, n (%) White1736 (82.63) Black188 (8.95) American Indian/Alaska Native, Asian/Pacific Islander144 (6.85) Unknown33 (1.57)SEER stage^a^, n (%) Local1740 (82.82) Regional245 (11.66) Distant89 (4.24) Unspecified27 (1.28)Lymph node examination, n (%) Not examined1406 (66.92) Negative574 (27.32) Positive92 (4.38) Unspecified29 (1.38)Tumor grade, n (%) Well differentiated282 (13.42) Moderately differentiated80 (3.81) Poorly differentiated41 (1.95) Undifferentiated13 (0.62) Unspecified1685 (80.20)Tumor multifocality^b^, n (%) No1657 (78.87) Yes352 (16.75) Unspecified92 (4.38)Tumor extension, n (%) Intrathyroidal1768 (84.15) Extrathyroidal301 (14.33) Unspecified32 (1.52)T-stage, n (%) T1486 (23.13) T2707 (33.65) T3708 (33.70) T498 (4.66) Unspecified102 (4.85)N-stage, n (%) N01913 (91.05) N1113 (5.38) Unspecified75 (3.57)M-stage, n (%) M01995 (94.95) M159 (2.81) Unspecified47 (2.24)Surgery, n (%) No29 (1.38) Total thyroidectomy1669 (79.44) Partial thyroidectomy382 (18.18) Unspecified21 (0.99)Radiotherapy, n (%) No850 (40.46) Radioactive iodine1155 (54.97) Unspecified96 (4.57)SEER, Surveillance, Epidemiology, and End Results^a^The local stage includes localized disease only. The regional stage includes regional disease by direct extension only, regional lymph nodes only, and regional disease by both direct extension and lymph node involvement. The distant stage includes disease that involve distant sites and/or lymph nodes^b^The tumor has multiple centers, and the foci are not contiguous

Comparison of patients with different SEER stages {#Sec7}
-------------------------------------------------

There was significant difference in age between patients with different SEER stages (*P* \< 0.001; Table [2](#Tab2){ref-type="table"}). The distant group had significantly more patients with male sex (*P* = 0.001), tumor multifocality (P \< 0.001), and tumor extension (P \< 0.001) compared to the local group (P \< 0.001; Table [2](#Tab2){ref-type="table"}). We also found that the TNM stage was consistent with the SEER stage (Table [2](#Tab2){ref-type="table"}). Table 2Patients with different SEER stagesCharacteristicsLocal disease (*n* = 1740)Regional disease (*n* = 245)Distant disease (*n* = 89)*P*-valueP^a^-valueP^b^-valueP^c^-valueAge (year)54 ± 14.861 ± 17.169 ± 13.5\< 0.001\< 0.001\< 0.001\< 0.001Gender, n (%)0.0010.0100.3700.005Male476 (27.4)87 (35.5)37 (41.6)Female1264 (72.6)158 (64.5)52 (58.4)Race, n (%)0.0160.0030.0640.898White1435 (82.5)206 (84.1)72 (82.6)Black168 (9.7)9 (3.7)10 (11.2)American Indian/Alaska Native, Asian/Pacific Islander111 (6.4)25 (10.2)7 (7.9)Unknown26 (1.5)5 (2.0)0Tumor multifocality, n (%)\< 0.001\< 0.001\< 0.001\< 0.001No1428 (82.1)173 (70.6)51 (57.3)Yes268 (15.4)58 (23.7)25 (28.1)Unspecified44 (2.5)14 (5.7)13 (14.6)Tumor extension, n (%)\< 0.001\< 0.0010.023\< 0.001Intrathyroidal1700 (97.7)49 (20.0)19 (21.3)Extrathyroidal40 (2.3)195 (79.6)66 (74.2)Unspecified01 (0.4)4 (4.5)T-stage, n (%)\< 0.001\< 0.001\< 0.001\< 0.001T1467 (26.8)16 (6.5)3 (3.4)T2678 (39.0)21 (8.6)8 (9.0)T3526 (30.2)164 (66.9)18 (20.2)T41 (0.1)42 (17.1)54 (60.7)Unspecified68 (3.9)2 (0.8)6 (6.7)N-stage, n (%)\< 0.001\< 0.0010.023\< 0.001N01703 (97.9)153 (62.4)52 (58.4)N1085 (34.7)28 (31.5)Unspecified37 (2.1)7 (2.9)9 (10.1)M-stage, n (%)\< 0.0010.167\< 0.001\< 0.001M01718 (98.7)240 (98.0)30 (33.7)M10059 (66.3)Unspecified22 (1.3)5 (2.0)0*SEER* Surveillance, Epidemiology, and End Results. P^a^, local stage vs. regional stage; P^b^, regional stage vs. distant stage; P^c^, local stage vs. distant stage

Comparison of patients with different surgical procedures {#Sec8}
---------------------------------------------------------

A total of 2051 patients were surgically managed, including 1669 (79.44%) cases of total thyroidectomy and 382 (18.18%) cases of partial thyroidectomy (Table [3](#Tab3){ref-type="table"}). Among the patients undergoing total thyroidectomy, 61.8% were married, versus 54.5% of married patients in the partial thyroidectomy group (*P* = 0.027). There were significantly more patients with T3, T4, N1, and M1 stages in the total thyroidectomy group than in the partial thyroidectomy group. Table 3Patients with different surgical proceduresCharacteristicsTotal thyroidectomy (*n* = 1669)Partial thyroidectomy (*n* = 382)P-valueAge55 ± 15.055 ± 16.50.136Gender, (%)0.556 Male484 (29.0)105 (27.5) Female1185 (71.0)277 (72.5)Race, n (%)0.667 White1387 (83.1)309 (80.9) Black148 (8.9)36 (9.4) American Indian/Alaska Native, Asian/Pacific Islander113 (6.8)30 (7.9) Unknown21 (1.3)7 (1.8)SEER stage, n (%)0.023 Local1388 (83.2)340 (89.0) Regional208 (12.5)35 (9.2) Distant68 (4.1)6 (1.6) Unspecified5 (0.3)1 (0.3)Tumor multifocality, n (%)0.072 No1324 (79.3)317 (83.0) Yes295 (17.7)50 (13.1) Unspecified50 (3.0)15 (3.9)Tumor extension, n (%)0.394 Intrathyroidal1420 (85.1)335 (87.7) Extrathyroidal241 (14.4)46 (12.0) Unspecified8 (0.5)1 (0.3)T-stage, n (%)0.022 T1391 (23.4)93 (24.3) T2566 (33.9)137 (35.9) T3577 (34.6)122 (31.9) T480 (4.8)8 (2.1) Unspecified55 (3.3)22 (5.8)N-stage, n (%)\< 0.001 N01535 (92.0)361 (94.5) N199 (5.9)6 (1.6) Unspecified35 (2.1)15 (3.9)M-stage, n (%)0.005 M01605 (96.2)368 (96.3) M144 (2.6)3 (0.8) Unspecified20 (1.2)11 (2.9)Radiotherapy, n (%)\< 0.001 No557 (33.4)262 (68.6) Radioactive iodine1033 (61.9)111 (29.1) Unspecified79 (4.7)9 (2.4)SEER: Surveillance Epidemiology and End Results

Patient survival {#Sec9}
----------------

The 5-year and 10-year cancer-specific survival (CSS) rates were 95.4 and 92.6%, respectively. Univariate survival analysis showed that age \> 45 years, late SEER stage, tumor extension, lymph node metastasis, and late TNM stage were associated with poor prognosis (all *P* \< 0.05). Female patients and surgically treated patients had significantly longer survival time (*P* \< 0.001). Multivariate analysis was used to identify the independent prognostic factors. The CSS was 134.36 ± 1.71 months for patients over 45 years of age, and 141.59 ± 1.23 months for patients under 45 years of age, suggesting that age ≥ 45 was an independent prognostic factor (hazard ratio \[HR\] = 3.595, 95% confidence interval: 1.415--9.131). In addition, regional disease, distant disease, T3 stage, and T4 stage were also independent prognostic factors (HR \> 1) (Table [4](#Tab4){ref-type="table"}). Table 4Univariate and multivariate Cox analyses of clinical features for cancer-related survival ratesFeaturesUnivariateMultivariateHR (95% CI)*P*-valueHR (95% CI)*P*-valueGender Male11 Female0.415 (0.278--0.619)\< 0.0010.614 (0.409--0.924)0.019Age (year)  \< 4511  ≥ 456.354 (2.582--15.635)\< 0.0014.204 (1.695--10.432)0.002Race White1---- Black0.960 (0.465--1.984)0.913---- Other0.646 (0.237--1.761)0.393----SEER stage Local11 Regional8.454 (4.823--14.817)\< 0.0018.015 (4.555--14.101)\< 0.001 Distant61.625 (3.772--31.568)\< 0.00146.219 (27.108--78.804)\< 0.001Tumor multifocality No1---- Yes1.334 (0.808--2.202)0.260----Tumor extension Intrathyroidal1---- Extrathyroidal12.342 (8.062--18.892)\< 0.001----Lymph node examination Not examined1---- Negative1.060 (0.646--1.741)0.817---- Positive6.029 (3.494--10.403)\< 0.001----T-stage T11---- T20.701 (0.226--2.173)0.538---- T34.866 (2.060--11.496)\< 0.001---- T442.305 (17.874--100.132)\< 0.001----N-stage N01---- N18.863 (5.561--14.124)\< 0.001----M-stage M01---- M132.934 (21.214--51.129)\< 0.001----Surgery No11 Total thyroidectomy0.085 (0.044--0.166)\< 0.0010.335 (0.152--0.741)0.007 Partial thyroidectomy0.046 (0.019--0.114)\< 0.0010.266 (0.096--0.742)0.011Radiotherapy No1---- Yes0.606 (0.405--0.905)0.014----*CI* confidence interval, *SEER* Surveillance Epidemiology and End Results

Kaplan-Meier curves were constructed to describe the survival of different groups. Figure [1](#Fig1){ref-type="fig"}a shows the CSS of all HCC patients. The 5-year and 10-year survival rates were 96.53 and 94.77% for female patients, and 92.61 and 86.88% for male patients (Fig. [1](#Fig1){ref-type="fig"}b). The 5-year and 10-year survival rates were 98.85 and 98.48% for patients under 45 years of age, and 94.28 and 90.51% for patients over 45 years of age (Fig. [1](#Fig1){ref-type="fig"}c). The 5-year and 10-year survival rates were 98.6 and 97.6% for patients with local disease, and 90.8 and 81.7% for patients with regional disease. However, the 5-year and 10-year survival rates were only 46.0 and 26.0% for patients with distant disease (Fig. [1](#Fig1){ref-type="fig"}d). The 5-year and 10-year survival rates were 95.6 and 92.7% for patients with negative lymph nodes, which was significantly higher than the 84.9 and 65.3% for those with positive lymph nodes (Fig. [1](#Fig1){ref-type="fig"}e). The 10-year survival rates of T1 and T2 stage patients were 97.57 and 98.13%. The 5-year and 10-year survival rates of T3 stage patients was 94.23 and 90.93%, respectively, which were significantly higher than the 5-year and 10-year survival rates of 59.78 and 46.45% for the T4 patients (Fig. [1](#Fig1){ref-type="fig"}f). There was no significant difference in 10-year survival rate between patients treated with total thyroidectomy and those treated with partial thyroidectomy (92.6% vs. 95.6%, *P* = 0.078). The 5-year and 10-year survival rates were 61.6 and 46.2% for non-surgically managed patients (Fig. [1](#Fig1){ref-type="fig"}g). The 5-year and 10-year survival rates were 96.28 and 93.86% for patients treated with RAI, and 94.18 and 90.78% for patients without RAI (Fig. [1](#Fig1){ref-type="fig"}h). Fig. 1Survival analysis. (**a**) Cancer-specific survival of the patients. (**b**) Cancer-specific survival of patients under and over 45 years of age (*P* = 0.007). (**c**) Cancer-specific survival of patients with different SEER stages (*P* \< 0.001). (**d**) Cancer-specific survival of patients with different lymph node status (*P* \< 0.001). (**e**) Cancer-specific survival of patients with different T stages (*P* \< 0.001). (**F**) Cancer-specific survival of surgically and non-surgically managed patients (*P* \< 0.001)

Discussion {#Sec10}
==========

Our study analyzed the basic characteristics, treatment methods, and survival of patients with HCC. From 2000 to 2015, 86 patients with thyroid Hurthle cell tumors were treated at the Peking Union Medical College Hospital, of which only 5 patients were diagnosed with thyroid HCC. Most literatures on HCC are case reports rather than clinical studies with large samples. Moreover, diagnosis of HCC relies on postoperative pathology. HCC is also characterized by multifocality with high risk of lymph node metastases and distant metastases \[[@CR7]\]. Approximately 10--20% of patients have metastases when diagnosed with HCC. Up to 37% of extrathyroidal extension HCC metastasizes to the cervical lymph nodes \[[@CR8]\]. There is still no consensus on the optimal treatment method for HCC, and the postoperative effect of radioactive iodine treatment is unclear.

The SEER database has been utilized to find the differences between HCC and other thyroid cancers \[[@CR9]--[@CR11]\]. Compared to other differentiated thyroid cancers, HCC is more aggressive with higher risk of distant metastasis and poor prognosis. For the first time, our study used the data of 2101 patients in the SEER database from 2004 to 2015 to describe the clinical characteristics of HCC patients and identify the prognostic factors of CSS.

HCC is more common in women with a male to female ratio of approximately 1:2 to 1:4 \[[@CR1]\], which is similar to our result of the ratio of male to female of 1:2.47. The first symptoms of HCC patients may include thyroid nodules or cervical lymphadenectasis. The SEER staging plays an important role in the treatment and prognosis of HCC. Therefore, our study also analyzed the relationship between the HCC clinical characteristics and SEER staging. The SEER staging integrates clinical and pathological data to provide accurate evaluation of the degree of disease. Our study found that older age, male sex, multifocal tumors, and extensive tumors were risk factors of late SEER stages. These results suggest that HCC has similar characteristics with other differentiated thyroid carcinomas.

Surgery is still the most effective treatment for HCC \[[@CR10], [@CR12]\]. Our study found no significant difference in CSS between patients treated with total thyroidectomy and those treated with partial thyroidectomy. This result suggests that the cancer-specific prognosis of HCC is not greatly affected by surgical methods. We speculate that partial thyroidectomy is sufficient for single, small tumors without extrathyroidal invasion. Compared with total thyroidectomy, partial thyroidectomy has fewer complications and less intraoperative injury, but has comparable survival time.

Radioactive iodine (RAI) is widely used for the treatment of differentiated thyroid cancer, especially papilla thyroid carcinoma. However, HCC is insensitive to RAI due to the low iodine uptake rate. Despite this, RAI is used in some patients after total thyroidectomy \[[@CR13]\]. The multivariate Cox analysis found that RAI treatment did not significantly improve the prognosis of HCC. However, the univariate Cox analysis showed that HCC patients can benefit from RAI treatment, which is consistent with previous findings \[[@CR12]\].

HCC is associated with a higher metastasis rate and a lower survival rate compared to other differentiated thyroid cancers \[[@CR14]\]. HCC with distant metastases has a 5-year mortality rate of up to 80% \[[@CR15]\]. Age, tumor size, and sex are prognostic factors of HCC, and tumor extension and recurrence often indicate poor prognosis and increased mortality \[[@CR16]\]. The reported 5-year and 10-year survival rates for nonmetastatic HCC are 85.1 and 71.1%, respectively \[[@CR17]\]. In our study, the 5-year and 10-year CSS rate for HCC were 95.4 and 92.6%, respectively. The higher survival rates in our study may be explained by the advancement in diagnosis and treatment of HCC in the last decade.

Our study has limitations. First, a small portion of the included patients had no data of race or tumor characteristics. For example, 80.2% of the patients had unclear tumor grades, and 2--5% had unclear TNM stages. Therefore, the SEER stage was adopted to describe the disease progression rather than the TNM stage. Second, the tumor grade data was excluded from the analysis due to incomplete information. Third, the SEER database has no detailed information on tumor multifocality, tumor extension, and completion thyroidectomy.

Conclusions {#Sec11}
===========

The SEER stage is an independent prognostic factor for HCC, and distant disease is associated with significantly poor prognosis. Age over 45 years, distant SEER stage, and late T-stage are independent risk factors for mortality in HCC. There was no significant difference in survival between patients treated with partial thyroidectomy and those treated with total thyroidectomy. RAI treatment may possibly improve patient survival after thyroidectomy.

HCC

:   Hurthle cell carcinoma

SEER

:   Surveillance, Epidemiology, and End Results
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